BioCryst Pharmaceuticals (NASDAQ:BCRX) Releases Quarterly Earnings Results, Hits Estimates

BioCryst Pharmaceuticals (NASDAQ:BCRX) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07), Briefing.com reports. The business had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. During the same period in the prior year, the company posted ($0.19) EPS. The company’s revenue for the quarter was up 35.1% on a year-over-year basis.

BioCryst Pharmaceuticals Trading Down 1.4 %

BCRX traded down $0.10 on Tuesday, hitting $7.25. 1,490,645 shares of the company’s stock were exchanged, compared to its average volume of 2,966,979. The stock has a fifty day moving average of $7.84 and a two-hundred day moving average of $6.95. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $8.88. The firm has a market cap of $1.50 billion, a PE ratio of -11.87 and a beta of 1.89.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. JMP Securities increased their target price on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $14.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Finally, Barclays lifted their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.67.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.